Anticoagulation in CKD and ESRD

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Anticoagulation management in nephrology patients, particularly those with chronic kidney disease (CKD) and atrial fibrillation, presents unique challenges.
• The efficacy and safety of anticoagulation in patients undergoing dialysis remain debated due to increased bleeding risks.

Purpose of the Study:

• To review the current literature on anticoagulation strategies for nephrology patients.
• To discuss the role of direct oral anticoagulants (DOACs) in CKD patients.
• To provide guidance on bridging anticoagulation for interventional procedures and anticoagulation in acute coronary syndromes.

Main Methods:

• Literature review of studies on anticoagulation in CKD and dialysis patients.
• Analysis of data regarding the use of direct oral anticoagulants (DOACs) in this population.
• Evaluation of evidence for unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in various clinical scenarios.

Main Results:

• CKD patients with atrial fibrillation generally benefit from anticoagulation.
• Anticoagulation in dialysis patients is controversial due to elevated bleeding risks; DOACs require cautious use pending further studies.
• UFH and renally dosed LMWH are suitable for acute coronary syndromes in non-end-stage CKD.
• UFH and LMWH show comparable efficacy for thromboembolic prophylaxis and extracorporeal circuit anticoagulation in dialysis patients.

Conclusions:

• Anticoagulation in CKD requires careful consideration of bleeding risks, especially in dialysis patients.
• DOACs offer new possibilities but need cautious application in advanced CKD and dialysis.
• A risk-based approach is recommended for bridging anticoagulation during interventional procedures.
• Heparin-based anticoagulants remain valuable options for specific indications in nephrology patients.